Opens in a new tab or window Geographic atrophy (GA) progressed more often ... and now we have a lot of evidence in terms of using OCT [optical coherence tomography] and getting much more ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

A large study that retrospectively analyzed the visual outcomes and rate of development of neovascular age-related macular ...

Pegcetacoplan (Syfovre) is now approved in Australia for treating geographic atrophy (GA) secondary to age-related macular ...

Geographic atrophy is a progressive form of AMD that can cause irreversible vision loss, with no treatments currently approved outside the US or Australia. The NDA submission is based on results ...

for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). If approved, ACP has the potential to become the first and only GA treatment available in Japan. GA is ...

Prevalence of geographic atrophy in Germany ... Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3.

For the first time, Australians with GA will have a treatment to slow the progression ... in October 2023. About SYFOVRE ® (pegcetacoplan injection) SYFOVRE ® (pegcetacoplan injection) is the ...

treatment with both every-other-month and monthly SYFOVRE slowed GA progression and showed a generally well-tolerated safety profile. The results were published in The Lancet in October 2023.